MeSH term
Frequency | Condition_Probility | Animals | 67 | 0.0 |
DNA Adducts | 6 | 8.0 |
DNA Damage | 4 | 0.0 |
DNA Repair | 3 | 0.0 |
Gene Expression | 9 | 0.0 |
Humans | 504 | 0.0 |
Acetylation | 146 | 28.0 |
Adult | 196 | 0.0 |
Arylamine N-Acetyltransferase/genetics | 47 | 79.0 |
Cells, Cultured | 7 | 0.0 |
*Chemical Industry | 2 | 11.0 |
Cross-Sectional Studies | 6 | 0.0 |
DNA Adducts/*analysis | 7 | 15.0 |
Male | 266 | 0.0 |
Netherlands | 3 | 1.0 |
Occupational Exposure/*adverse effects | 13 | 13.0 |
Phenotype | 107 | 1.0 |
Questionnaires | 10 | 1.0 |
Random Allocation | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 119 | 0.0 |
Risk Factors | 114 | 1.0 |
Aged | 152 | 0.0 |
Aged, 80 and over | 41 | 0.0 |
Arylamine N-Acetyltransferase/*genetics | 187 | 90.0 |
Carcinoma, Squamous Cell/enzymology/*genetics | 3 | 18.0 |
Cytochrome P-450 CYP1A1/genetics | 13 | 13.0 |
Female | 271 | 0.0 |
*Genetic Predisposition to Disease | 32 | 2.0 |
Genotype | 240 | 2.0 |
Glutathione Transferase/*genetics | 51 | 7.0 |
Middle Aged | 221 | 0.0 |
Neoplasm Proteins/*genetics | 5 | 0.0 |
*Polymorphism, Genetic | 102 | 2.0 |
Arylamine N-Acetyltransferase/*biosynthesis | 3 | 100.0 |
Blotting, Western | 13 | 0.0 |
Case-Control Studies | 98 | 1.0 |
Immunohistochemistry | 6 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 12 | 0.0 |
Smoking/*metabolism | 2 | 4.0 |
African Continental Ancestry Group/*genetics | 5 | 1.0 |
Alleles | 88 | 1.0 |
Comparative Study | 62 | 0.0 |
European Continental Ancestry Group/*genetics | 8 | 2.0 |
Genetic Predisposition to Disease | 35 | 1.0 |
Isoenzymes/*genetics | 27 | 6.0 |
Polymorphism, Genetic/genetics | 14 | 2.0 |
Research Support, Non-U.S. Gov't | 310 | 0.0 |
Acute Disease | 2 | 0.0 |
Cytochrome P-450 CYP1A2/*metabolism | 10 | 12.0 |
Drug Therapy, Combination | 3 | 0.0 |
Treatment Outcome | 2 | 0.0 |
DNA/blood | 4 | 2.0 |
DNA Repair/*genetics | 4 | 1.0 |
European Continental Ancestry Group | 3 | 0.0 |
Leukocytes/physiology | 2 | 3.0 |
Risk | 15 | 1.0 |
Xenobiotics/*pharmacokinetics | 3 | 18.0 |
Acetyltransferases/*genetics | 30 | 56.0 |
*Diet | 9 | 4.0 |
Incidence | 15 | 1.0 |
*Meat | 11 | 26.0 |
Netherlands/epidemiology | 2 | 1.0 |
Polymorphism, Genetic | 95 | 2.0 |
Prospective Studies | 10 | 0.0 |
Sex Factors | 13 | 0.0 |
Smoking/*adverse effects | 31 | 14.0 |
Arylamine N-Acetyltransferase/*metabolism | 25 | 78.0 |
Biological Markers | 10 | 0.0 |
Cattle | 8 | 0.0 |
Cookery | 12 | 22.0 |
Mutagenicity Tests/methods | 2 | 16.0 |
Acetyltransferases/genetics/*metabolism | 2 | 8.0 |
Amines/*pharmacokinetics | 3 | 75.0 |
Arylamine N-Acetyltransferase/genetics/metabolism | 9 | 60.0 |
*Arylsulfotransferase | 5 | 13.0 |
Biotransformation | 41 | 7.0 |
Gene Expression Regulation, Enzymologic | 11 | 1.0 |
Imidazoles/metabolism | 3 | 23.0 |
Immunoblotting | 2 | 0.0 |
Isoenzymes/genetics/metabolism | 5 | 3.0 |
Mutagenicity Tests | 10 | 6.0 |
Sulfotransferases/genetics/*metabolism | 2 | 25.0 |
Cytochrome P-450 CYP2D6/*genetics | 6 | 10.0 |
Disease Progression | 2 | 0.0 |
English Abstract | 23 | 0.0 |
Xenobiotics/metabolism | 10 | 22.0 |
Anti-Infective Agents/*adverse effects | 2 | 40.0 |
Trimethoprim-Sulfamethoxazole Combination/*adverse effects | 2 | 33.0 |
Pharmacogenetics | 4 | 3.0 |
Amines/*toxicity | 3 | 27.0 |
Bladder Neoplasms/*chemically induced | 2 | 66.0 |
Carcinogens/*toxicity | 8 | 7.0 |
Cytochrome P-450 CYP1A2/metabolism | 10 | 10.0 |
Recombinant Proteins/metabolism | 9 | 0.0 |
*Chromosome Aberrations | 7 | 1.0 |
Xenobiotics/*metabolism | 10 | 18.0 |
Laryngeal Neoplasms/*genetics | 2 | 11.0 |
*Polymorphism, Restriction Fragment Length | 13 | 1.0 |
Oxidoreductases/*genetics | 2 | 2.0 |
Paint/adverse effects | 2 | 100.0 |
Retrospective Studies | 5 | 0.0 |
Solvents/*adverse effects | 2 | 22.0 |
Aminobiphenyl Compounds/*pharmacology | 2 | 66.0 |
DNA Adducts/*metabolism | 8 | 17.0 |
Diet | 13 | 3.0 |
Mass Fragmentography | 5 | 2.0 |
Smoking/metabolism | 5 | 9.0 |
Imidazoles/*urine | 2 | 25.0 |
DNA, Neoplasm/genetics | 5 | 0.0 |
Gene Frequency | 53 | 1.0 |
Genetic Predisposition to Disease/*genetics | 6 | 1.0 |
Smoking | 17 | 4.0 |
Statistics | 2 | 0.0 |
Adolescent | 45 | 0.0 |
Polymerase Chain Reaction | 94 | 0.0 |
Sequence Analysis, DNA | 5 | 0.0 |
DNA/blood/genetics | 2 | 3.0 |
DNA Primers | 21 | 0.0 |
Linkage Disequilibrium | 4 | 0.0 |
North Carolina | 2 | 8.0 |
Polymorphism, Single Nucleotide | 3 | 0.0 |
Reproducibility of Results | 5 | 0.0 |
Czech Republic | 3 | 6.0 |
DNA/metabolism | 4 | 0.0 |
Arylamine N-Acetyltransferase/*genetics/metabolism | 43 | 82.0 |
Cytochrome P-450 Enzyme System/*genetics/metabolism | 7 | 5.0 |
Glutathione Transferase/*genetics/metabolism | 9 | 11.0 |
Taiwan/epidemiology | 3 | 2.0 |
Glutathione Transferase/genetics | 27 | 9.0 |
Isoenzymes/*genetics/metabolism | 6 | 10.0 |
Odds Ratio | 43 | 4.0 |
Child | 14 | 0.0 |
Child, Preschool | 11 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics | 8 | 1.0 |
Disease Susceptibility | 14 | 1.0 |
Infant | 7 | 0.0 |
NAD(P)H Dehydrogenase (Quinone)/*genetics | 3 | 4.0 |
Prognosis | 4 | 0.0 |
Survival Rate | 2 | 0.0 |
Cytochrome P-450 CYP1A2/*genetics | 5 | 13.0 |
Heterocyclic Compounds/metabolism | 2 | 40.0 |
Polymorphism, Genetic/*genetics | 32 | 2.0 |
Quinolines/*metabolism | 3 | 17.0 |
Age Factors | 12 | 0.0 |
Breast Neoplasms/*genetics | 3 | 0.0 |
Carcinogens | 2 | 2.0 |
Cytochrome P-450 CYP1A1/*genetics | 5 | 2.0 |
*DNA Adducts | 3 | 8.0 |
Linear Models | 2 | 0.0 |
Amines/*metabolism/toxicity | 2 | 50.0 |
Asian Continental Ancestry Group/*genetics | 5 | 1.0 |
China/epidemiology/ethnology | 2 | 66.0 |
Occupational Exposure | 4 | 5.0 |
*Genotype | 11 | 5.0 |
Neoplasms/genetics/metabolism | 2 | 10.0 |
Pharmaceutical Preparations/*metabolism | 4 | 4.0 |
*Phenotype | 3 | 1.0 |
Polymorphism, Single Nucleotide/*genetics | 4 | 1.0 |
Severity of Illness Index | 2 | 0.0 |
Chi-Square Distribution | 4 | 0.0 |
Logistic Models | 12 | 1.0 |
Metabolic Detoxication, Drug/genetics | 5 | 25.0 |
Polymorphism, Restriction Fragment Length | 50 | 2.0 |
Statistics, Nonparametric | 3 | 0.0 |
Computer Simulation | 3 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Structure-Activity Relationship | 7 | 0.0 |
Substrate Specificity | 16 | 0.0 |
Age Distribution | 4 | 1.0 |
Cohort Studies | 11 | 0.0 |
Confidence Intervals | 8 | 2.0 |
Epoxide Hydrolases/*genetics/metabolism | 2 | 28.0 |
Reference Values | 12 | 0.0 |
Risk Assessment | 14 | 1.0 |
Sex Distribution | 4 | 1.0 |
Time Factors | 11 | 0.0 |
Dapsone/blood/metabolism | 3 | 100.0 |
Turkey | 2 | 1.0 |
Germ-Line Mutation | 3 | 0.0 |
Caffeine/*diagnostic use | 2 | 66.0 |
Evolution, Molecular | 2 | 0.0 |
Indians, Central American/*genetics | 3 | 25.0 |
Indians, South American/*genetics | 3 | 4.0 |
Models, Genetic | 3 | 0.0 |
Panama | 3 | 42.0 |
Variation (Genetics) | 13 | 0.0 |
Arylamine N-Acetyltransferase/blood/*genetics | 3 | 100.0 |
European Continental Ancestry Group/genetics | 14 | 2.0 |
Pregnancy | 15 | 0.0 |
Pregnancy Trimester, First | 2 | 0.0 |
Sweden | 3 | 1.0 |
Carcinogens, Environmental/*adverse effects | 2 | 50.0 |
Colorectal Neoplasms/*etiology/genetics | 2 | 66.0 |
Cytochrome P-450 CYP1A2/*genetics/metabolism | 2 | 25.0 |
*Environmental Exposure | 3 | 4.0 |
Enzyme Induction | 4 | 0.0 |
Bladder Neoplasms/*etiology | 2 | 66.0 |
England/epidemiology | 2 | 3.0 |
Epidemiologic Studies | 3 | 6.0 |
Germany/epidemiology | 2 | 1.0 |
*Occupational Exposure | 8 | 5.0 |
Cytochrome P-450 Enzyme System/genetics | 8 | 7.0 |
*Gene Frequency | 4 | 0.0 |
Linkage (Genetics) | 10 | 0.0 |
Neoplasms/*genetics | 3 | 1.0 |
Acetyltransferases/genetics/metabolism | 4 | 36.0 |
Cell Line | 9 | 0.0 |
Cytochrome P-450 CYP1A2/genetics/metabolism | 3 | 17.0 |
Glutathione Transferase/genetics/metabolism | 6 | 5.0 |
Quinolines/*pharmacokinetics | 4 | 40.0 |
Arylamine N-Acetyltransferase/chemistry/*genetics | 2 | 100.0 |
Point Mutation | 4 | 0.0 |
Bladder Neoplasms/*etiology/genetics | 3 | 75.0 |
Pilot Projects | 8 | 1.0 |
Regression Analysis | 10 | 0.0 |
Smoking/adverse effects | 17 | 5.0 |
*DNA Damage | 4 | 0.0 |
Population Surveillance | 3 | 1.0 |
Xenobiotics/*adverse effects | 2 | 66.0 |
*Genes, ras | 3 | 1.0 |
Isoenzymes/genetics | 10 | 3.0 |
*Mutation | 18 | 0.0 |
*Polymerase Chain Reaction | 2 | 0.0 |
Carcinogens/*adverse effects | 3 | 13.0 |
Cocarcinogenesis | 3 | 11.0 |
Environmental Exposure/*adverse effects | 3 | 10.0 |
Models, Statistical | 3 | 1.0 |
Polymorphism, Single Nucleotide/genetics | 3 | 1.0 |
Alzheimer Disease/*genetics | 3 | 0.0 |
Asian Continental Ancestry Group | 3 | 1.0 |
China | 12 | 2.0 |
Algorithms | 2 | 0.0 |
Chromatography, High Pressure Liquid | 12 | 0.0 |
Japan | 8 | 0.0 |
Models, Biological | 7 | 0.0 |
Spectrophotometry, Ultraviolet | 2 | 1.0 |
DNA/genetics/isolation & purification | 2 | 0.0 |
Predictive Value of Tests | 5 | 0.0 |
Bladder Neoplasms/*enzymology/genetics | 2 | 40.0 |
Germany | 3 | 0.0 |
Occupational Exposure/adverse effects | 3 | 13.0 |
Chromosomes, Human, Pair 8/*genetics | 2 | 1.0 |
Caffeine/*metabolism | 6 | 22.0 |
Theophylline/urine | 2 | 33.0 |
Uracil/*analogs & derivatives/urine | 3 | 75.0 |
Xanthine Oxidase/*metabolism | 5 | 29.0 |
Xanthines/urine | 6 | 46.0 |
DNA Mutational Analysis | 8 | 0.0 |
Hepatitis, Toxic/*genetics | 2 | 100.0 |
Liver Function Tests | 2 | 1.0 |
Data Interpretation, Statistical | 2 | 0.0 |
Genes, Tumor Suppressor/genetics | 2 | 1.0 |
Laryngeal Neoplasms/genetics | 2 | 15.0 |
Oncogenes/genetics | 2 | 2.0 |
Acetyltransferases/*genetics/*metabolism | 2 | 40.0 |
Genetic Predisposition to Disease/genetics | 7 | 1.0 |
Biological Markers/analysis | 2 | 0.0 |
*Risk Assessment | 2 | 11.0 |
Epidemiology, Molecular | 5 | 5.0 |
Genetic Screening | 4 | 0.0 |
Infant, Newborn | 9 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 20 | 0.0 |
*Arylamine N-Acetyltransferase | 2 | 18.0 |
Chromosome Aberrations | 2 | 0.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
*Ligases | 2 | 1.0 |
Loss of Heterozygosity | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
*Ubiquitin-Protein Ligases | 2 | 0.0 |
Analysis of Variance | 5 | 0.0 |
Colorectal Neoplasms/*epidemiology/*genetics | 2 | 40.0 |
4-Aminobenzoic Acid/pharmacokinetics | 2 | 100.0 |
Breast/*enzymology | 2 | 13.0 |
Isoenzymes/*metabolism | 9 | 3.0 |
Kinetics | 33 | 0.0 |
Tumor Cells, Cultured | 7 | 0.0 |
Arylamine N-Acetyltransferase/drug effects/*genetics/metabolism | 2 | 100.0 |
Bladder Neoplasms/enzymology/*genetics | 4 | 30.0 |
Haplotypes | 3 | 0.0 |
Acetyltransferases/genetics | 7 | 18.0 |
Apolipoproteins E/genetics | 2 | 0.0 |
Cytochrome P-450 CYP2D6/genetics | 7 | 22.0 |
Neoplasm Staging | 4 | 0.0 |
Endometriosis/*genetics | 2 | 11.0 |
Chromatography, High Pressure Liquid/methods | 2 | 1.0 |
Uracil/analogs & derivatives/urine | 6 | 75.0 |
Chromosome Mapping | 3 | 0.0 |
*Polymorphism, Single Nucleotide | 4 | 0.0 |
Arylamine N-Acetyltransferase/*physiology | 3 | 60.0 |
Blotting, Northern | 3 | 0.0 |
Blotting, Southern | 5 | 0.0 |
Recombinant Proteins | 2 | 0.0 |
Sulfamethazine/pharmacology | 3 | 100.0 |
California/epidemiology | 2 | 5.0 |
Comorbidity | 2 | 0.0 |
Genetic Predisposition to Disease/epidemiology | 3 | 3.0 |
Arylamine N-Acetyltransferase/genetics/*metabolism | 14 | 87.0 |
Caffeine/metabolism | 4 | 14.0 |
Breast Neoplasms/*enzymology/epidemiology/*genetics | 2 | 50.0 |
Carcinogens/*metabolism | 11 | 14.0 |
Environmental Exposure | 8 | 5.0 |
Menopause | 2 | 0.0 |
Caffeine/urine | 2 | 50.0 |
Liver/metabolism | 6 | 0.0 |
Base Sequence | 61 | 0.0 |
*Pharmacogenetics | 6 | 12.0 |
Colorectal Neoplasms/*genetics | 8 | 3.0 |
*DNA-Binding Proteins | 4 | 0.0 |
Heterozygote | 12 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/metabolism | 4 | 9.0 |
Genes, p53/genetics | 2 | 0.0 |
*Genetic Screening | 2 | 1.0 |
Sampling Studies | 2 | 1.0 |
DNA Adducts/*genetics | 2 | 28.0 |
Hypoxanthine Phosphoribosyltransferase/*genetics | 5 | 10.0 |
Probability | 2 | 0.0 |
Caffeine/pharmacokinetics | 5 | 38.0 |
Enzyme Activation | 2 | 0.0 |
Arylamine N-Acetyltransferase/*genetics/*metabolism | 10 | 71.0 |
Liver/enzymology | 8 | 1.0 |
Mutation | 22 | 0.0 |
*Aryl Hydrocarbon Hydroxylases | 5 | 0.0 |
Metabolic Detoxication, Drug | 5 | 6.0 |
Polymerase Chain Reaction/methods | 5 | 0.0 |
Arylamine N-Acetyltransferase/metabolism | 9 | 42.0 |
Biotransformation/*genetics | 2 | 33.0 |
Cytochrome P-450 Enzyme System/metabolism | 2 | 0.0 |
Peroxidase/metabolism | 3 | 2.0 |
Sulfotransferases/metabolism | 3 | 21.0 |
Tumor Markers, Biological | 2 | 0.0 |
Administration, Oral | 2 | 0.0 |
Animals, Congenic | 3 | 17.0 |
Disease Models, Animal | 3 | 0.0 |
Hamsters | 15 | 0.0 |
Homozygote | 12 | 0.0 |
Mesocricetus | 7 | 4.0 |
Tissue Distribution | 3 | 0.0 |
DNA/drug effects | 2 | 9.0 |
Sequence Analysis, DNA/*methods | 3 | 4.0 |
Neoplasms/epidemiology/*genetics | 2 | 25.0 |
Sensitivity and Specificity | 7 | 0.0 |
Meat/adverse effects | 3 | 37.0 |
Organ Specificity | 3 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Vegetables | 2 | 8.0 |
Colon/enzymology | 2 | 7.0 |
Colorectal Neoplasms/enzymology/*genetics | 5 | 31.0 |
Epithelium/enzymology | 2 | 5.0 |
Evaluation Studies | 3 | 0.0 |
Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 0.0 |
United States | 5 | 0.0 |
Smoking/*adverse effects/metabolism | 2 | 28.0 |
DNA/analysis | 5 | 0.0 |
Molecular Biology | 4 | 1.0 |
Pharmaceutical Preparations/metabolism | 3 | 9.0 |
*Alleles | 11 | 0.0 |
Ethnic Groups | 5 | 2.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Carrier Proteins/genetics | 2 | 0.0 |
Catechol O-Methyltransferase/genetics | 2 | 6.0 |
DNA, Mitochondrial/genetics | 2 | 4.0 |
Parkinson Disease/*genetics | 3 | 3.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Body Mass Index | 3 | 0.0 |
Breast Neoplasms/*etiology/genetics | 3 | 37.0 |
Tobacco Smoke Pollution/*adverse effects | 3 | 9.0 |
Asthma/*genetics | 2 | 3.0 |
Hypersensitivity, Immediate/*genetics | 2 | 14.0 |
*Epidemiology, Molecular | 3 | 17.0 |
United States/epidemiology | 5 | 1.0 |
Isoenzymes/metabolism | 4 | 0.0 |
Likelihood Functions | 3 | 1.0 |
Cytosol/metabolism | 8 | 1.0 |
Glutathione Transferase/metabolism | 3 | 0.0 |
In Vitro | 13 | 0.0 |
Mice | 13 | 0.0 |
Mice, Inbred Strains | 3 | 0.0 |
Rats | 13 | 0.0 |
Rats, Inbred F344 | 5 | 1.0 |
Acetyltransferases/*genetics/metabolism | 8 | 47.0 |
Biological Markers/blood | 3 | 0.0 |
Enzymes/*genetics/metabolism | 3 | 33.0 |
Smoking/genetics | 3 | 15.0 |
Caffeine/*pharmacokinetics | 2 | 11.0 |
Cytochrome P-450 CYP1A2/genetics/*metabolism | 4 | 16.0 |
*Vegetables | 2 | 15.0 |
Amino Acid Sequence | 11 | 0.0 |
Enzyme Stability | 9 | 4.0 |
Isoenzymes/genetics/*metabolism | 5 | 5.0 |
Molecular Sequence Data | 49 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Asia/epidemiology | 2 | 12.0 |
Smoking/epidemiology | 4 | 6.0 |
Head and Neck Neoplasms/enzymology/*genetics | 2 | 33.0 |
Gestational Age | 2 | 0.0 |
Asbestos/*adverse effects | 3 | 21.0 |
Bladder Neoplasms/epidemiology/*genetics | 2 | 25.0 |
Imidazoles/*toxicity | 2 | 4.0 |
Mutagens/*toxicity | 2 | 1.0 |
Quinoxalines/*toxicity | 2 | 28.0 |
Isoniazid/*therapeutic use | 2 | 40.0 |
In Situ Hybridization | 3 | 0.0 |
*Genetics, Population | 4 | 1.0 |
Coke/*adverse effects | 2 | 33.0 |
Cotinine/urine | 2 | 28.0 |
*Life Style | 2 | 3.0 |
Inflammatory Bowel Diseases/drug therapy | 2 | 66.0 |
Colorectal Neoplasms/genetics | 2 | 4.0 |
Postmenopause | 4 | 2.0 |
Fetal Blood/metabolism | 3 | 4.0 |
Age of Onset | 3 | 0.0 |
Bladder Neoplasms/etiology | 3 | 42.0 |
Carcinogens/metabolism | 8 | 25.0 |
Terminology | 2 | 1.0 |
DNA Adducts/*blood | 2 | 18.0 |
*Food Habits | 4 | 18.0 |
Italy/epidemiology | 2 | 0.0 |
Leukocytes/*chemistry | 2 | 7.0 |
Socioeconomic Factors | 2 | 1.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Multivariate Analysis | 6 | 0.0 |
Life Style | 5 | 3.0 |
Cytosol/enzymology | 7 | 3.0 |
Sex Characteristics | 2 | 0.0 |
Proteins/genetics | 2 | 0.0 |
Gene Frequency/genetics | 3 | 0.0 |
Genetics, Population | 5 | 1.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
DNA Primers/genetics | 6 | 0.0 |
*Gene Deletion | 2 | 0.0 |
Pyridines/metabolism | 2 | 20.0 |
Schizosaccharomyces/genetics/metabolism | 3 | 23.0 |
Cytochrome P-450 CYP1A2/genetics | 3 | 27.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Mutagens/*metabolism | 10 | 27.0 |
Oxidation-Reduction | 3 | 0.0 |
Quinoxalines/*metabolism | 3 | 33.0 |
DNA Adducts/analysis | 2 | 15.0 |
Bladder Neoplasms/*genetics/pathology | 3 | 7.0 |
Chromosomes, Human, Pair 8/genetics | 2 | 2.0 |
Plants, Toxic | 3 | 7.0 |
Tobacco | 3 | 10.0 |
Cytochrome P-450 CYP2D6/genetics/metabolism | 3 | 20.0 |
Mixed Function Oxygenases/genetics/metabolism | 4 | 18.0 |
Amines/adverse effects | 2 | 40.0 |
China/ethnology | 2 | 1.0 |
Jews/genetics | 2 | 2.0 |
4-Aminobenzoic Acid/metabolism | 7 | 53.0 |
Cloning, Molecular | 16 | 0.0 |
Sulfamethazine/metabolism | 8 | 100.0 |
Folic Acid/*metabolism | 2 | 4.0 |
Glutamates/*metabolism | 2 | 20.0 |
Mice, Inbred C57BL | 4 | 0.0 |
Cytochrome P-450 CYP2E1/*genetics | 6 | 4.0 |
Heat | 4 | 0.0 |
DNA Adducts/metabolism | 2 | 5.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Imidazoles/*metabolism | 3 | 9.0 |
Pyridines/*metabolism | 2 | 20.0 |
Chromosome Deletion | 2 | 0.0 |
Genetic Markers | 9 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Prevalence | 7 | 0.0 |
Parity | 2 | 1.0 |
France | 2 | 0.0 |
Arylamine N-Acetyltransferase/*biosynthesis/genetics | 2 | 100.0 |
Carcinogens/metabolism/pharmacology | 2 | 66.0 |
Fluorenes/metabolism | 5 | 45.0 |
Prostate/*enzymology | 2 | 1.0 |
Rats, Inbred WKY | 2 | 2.0 |
Arylamine N-Acetyltransferase/*genetics/physiology | 2 | 100.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Environmental Exposure/adverse effects | 2 | 12.0 |
Food Habits | 3 | 11.0 |
Fluorenes/pharmacokinetics/toxicity | 2 | 100.0 |
Poland | 5 | 3.0 |
Italy | 4 | 0.0 |
Alcohol Drinking | 2 | 1.0 |
*Chromosomes, Human, Pair 8 | 2 | 0.0 |
Air Pollution/*adverse effects | 3 | 37.0 |
Denmark | 2 | 1.0 |
Urban Population | 2 | 1.0 |
Colorectal Neoplasms/*enzymology/*genetics | 2 | 18.0 |
Exons | 3 | 0.0 |
Acetyltransferases/*metabolism | 8 | 10.0 |
Caffeine/metabolism/*urine | 2 | 33.0 |
Epoxide Hydrolases/*genetics | 2 | 6.0 |
Neoplasms/*etiology | 2 | 7.0 |
Sulfotransferases/*genetics | 2 | 5.0 |
Cats | 2 | 0.0 |
DNA | 3 | 0.0 |
Liver/*enzymology | 3 | 0.0 |
Rabbits | 6 | 0.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Acetyltransferases/metabolism | 3 | 4.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Mutagens/metabolism | 2 | 7.0 |
DNA/genetics | 2 | 0.0 |
Acetyltransferases/*biosynthesis/genetics | 2 | 100.0 |
Animals, Newborn | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Imidazoles/*pharmacokinetics | 2 | 14.0 |
Mutagens/*pharmacokinetics | 2 | 25.0 |
Transfection | 4 | 0.0 |
Portugal | 2 | 3.0 |
*Smoking | 4 | 4.0 |
Gene Deletion | 2 | 0.0 |
Cytochrome P-450 CYP2D6/*genetics/metabolism | 2 | 8.0 |
Cytochrome P-450 CYP2E1/genetics | 3 | 7.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Mixed Function Oxygenases/genetics | 3 | 7.0 |
*Point Mutation | 6 | 0.0 |
Placenta/*enzymology | 2 | 2.0 |
Lymphocytes/physiology | 3 | 3.0 |
Japan/epidemiology | 4 | 1.0 |
Cytochrome P-450 Enzyme System/*metabolism | 7 | 1.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Asian Continental Ancestry Group/genetics | 5 | 1.0 |
India | 4 | 1.0 |
Malaysia | 2 | 5.0 |
Tumor Markers, Biological/genetics | 2 | 2.0 |
Phosphorus Radioisotopes | 2 | 3.0 |
African Continental Ancestry Group/genetics | 5 | 1.0 |
Meat/*adverse effects | 2 | 40.0 |
Adenoma/enzymology/*genetics | 2 | 50.0 |
Amines/metabolism | 4 | 30.0 |
California | 2 | 4.0 |
Continental Population Groups | 2 | 1.0 |
*Variation (Genetics) | 4 | 0.0 |
Bladder Neoplasms/*genetics | 2 | 2.0 |
Genes, p53/*genetics | 3 | 0.0 |
Carcinogens/*pharmacokinetics | 4 | 17.0 |
Fluorenes/pharmacokinetics | 2 | 66.0 |
Isoniazid/pharmacology | 2 | 22.0 |
North Carolina/epidemiology | 2 | 11.0 |
Amines/*metabolism | 3 | 16.0 |
Meat | 3 | 9.0 |
Swine | 2 | 0.0 |
Colonic Neoplasms/enzymology/*genetics | 2 | 18.0 |
Aminobiphenyl Compounds/*metabolism | 2 | 33.0 |
*Genes, p53 | 3 | 0.0 |
Ultraviolet Rays | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/genetics | 2 | 8.0 |
Arylamine N-Acetyltransferase/*deficiency/*genetics | 2 | 100.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Sulfotransferases/genetics | 2 | 33.0 |
Mutagens/*analysis | 3 | 17.0 |
Arabs/*genetics | 2 | 7.0 |
Gene Expression Regulation, Enzymologic/*genetics | 2 | 3.0 |
Arylamine N-Acetyltransferase/*genetics/pharmacology | 3 | 100.0 |
Quinoxalines/*urine | 2 | 50.0 |
Acyltransferases/metabolism | 3 | 23.0 |
Benzidines/metabolism | 2 | 33.0 |
Benzo(a)pyrene/metabolism | 2 | 11.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Arylamine N-Acetyltransferase/biosynthesis/*genetics | 3 | 100.0 |
Heterocyclic Compounds/*metabolism | 3 | 30.0 |
Colorectal Neoplasms/*etiology | 2 | 33.0 |
Protein Denaturation | 4 | 1.0 |
Binding Sites/genetics | 2 | 0.0 |
Sulfasalazine/*therapeutic use | 2 | 28.0 |
*Genetic Markers | 2 | 0.0 |
Colorectal Neoplasms/*etiology/*genetics | 2 | 28.0 |
United Arab Emirates | 2 | 20.0 |
Restriction Mapping | 3 | 0.0 |
Adenomatous Polyposis Coli/*genetics | 2 | 3.0 |
Pedigree | 2 | 0.0 |
Adenocarcinoma/*enzymology/genetics | 2 | 16.0 |
DNA Probes | 3 | 0.0 |
Bladder Neoplasms/*enzymology/*genetics | 2 | 66.0 |
Metabolic Detoxication, Drug/*genetics | 3 | 33.0 |
Dogs | 3 | 0.0 |
Adenoma/*genetics | 2 | 2.0 |
Poly A/*metabolism | 2 | 9.0 |
Urinalysis | 3 | 18.0 |
Mathematics | 2 | 1.0 |
Bladder/*metabolism | 2 | 15.0 |
Caffeine/blood/*metabolism/urine | 2 | 50.0 |
Saliva/metabolism | 2 | 6.0 |
Carcinogens/*metabolism/toxicity | 2 | 12.0 |
Escherichia coli | 3 | 0.0 |
*Cocarcinogenesis | 2 | 9.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics | 2 | 2.0 |
Cytochrome P-450 CYP1A1 | 2 | 4.0 |
Environmental Monitoring | 2 | 5.0 |
Oxidoreductases, N-Demethylating/genetics/metabolism | 2 | 11.0 |
Cytochrome P-450 CYP2D6 | 4 | 5.0 |
DNA Primers/chemistry | 3 | 0.0 |
Cytochrome P-450 CYP1A2 | 10 | 11.0 |
Oxidoreductases/*metabolism | 3 | 7.0 |
Colombia | 2 | 4.0 |
Salmonella typhimurium/genetics | 3 | 21.0 |
Genetic Vectors | 2 | 0.0 |
Recombinant Proteins/genetics/metabolism | 3 | 0.0 |
Genes, Regulator | 2 | 1.0 |
Cricetulus | 3 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Breast Neoplasms/enzymology/*genetics | 2 | 7.0 |
Amines/adverse effects/pharmacokinetics | 2 | 100.0 |
Oxidoreductases/genetics | 2 | 5.0 |
Enzyme Induction/drug effects | 2 | 0.0 |
Aging | 2 | 0.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
Escherichia coli/genetics | 2 | 0.0 |
Isoenzymes/*genetics/*metabolism | 2 | 12.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Molecular Structure | 2 | 0.0 |
Pyrenes/*analysis | 2 | 33.0 |
Cytochrome P-450 Enzyme System/genetics/*metabolism | 2 | 1.0 |
Epoxide Hydrolases/genetics | 2 | 15.0 |
Aryl Hydrocarbon Hydroxylases/genetics/metabolism | 2 | 11.0 |
Mutation/genetics | 2 | 0.0 |
Area Under Curve | 2 | 0.0 |
Glutathione Transferase/*genetics/pharmacology | 2 | 18.0 |
Registries | 2 | 0.0 |
Methyltransferases/genetics | 2 | 11.0 |
DNA Adducts/analysis/drug effects | 2 | 100.0 |
*Transcription Factors | 2 | 0.0 |
Gene Frequency/*genetics | 2 | 1.0 |
Arylamine N-Acetyltransferase/genetics/physiology | 2 | 100.0 |
